Innogen’s strategy centers on a "from 0 to 1" innovation model, anchored by its core product, efsubaglutide alfa. The ultra-long-acting GLP-1 receptor agonist, already approved in China for type 2 diabetes, serves as a test case for whether domestic R&D can withstand international scrutiny. Dr. Wang argues that the next phase of industry growth depends on moving past generic biosimilars to create molecules that meet global standards for clinical value, data integrity, and patient-centric outcomes.

To bridge the gap between regional success and global presence, the company is actively testing its portfolio in diverse clinical environments. Beyond its domestic pipeline, Innogen is currently conducting Phase 2 obesity studies in Australia and registration-focused bridging trials in Brazil. These efforts aim to validate efficacy and safety across different patient populations while navigating complex regulatory landscapes in emerging markets. According to the company, success in these regions requires more than approvals; it demands a robust infrastructure for supply, physician education, and long-term safety monitoring to ensure sustainable access for patients.